AbstractThe 2006 National Institutes of Health (NIH) Consensus paper presented recommendations by the Ancillary Therapy and Supportive Care Working Group to support clinical research trials in chronic graft-versus-host disease (GVHD). Topics covered in that inaugural effort included the prevention and management of infections and common complications of chronic GVHD, as well as recommendations for patient education and appropriate follow-up. Given the new literature that has emerged during the past 8 years, we made further organ-specific refinements to these guidelines. Minimum frequencies are suggested for monitoring key parameters relevant to chronic GVHD during systemic immunosuppressive therapy and, thereafter, referral to existing late...
: Positive results from recent clinical trials have significantly expanded current therapeutic optio...
AbstractThe Ancillary Therapy and Supportive Care Working Group had 3 goals: (1) to establish guidel...
: Positive results from recent clinical trials have significantly expanded current therapeutic optio...
AbstractThe 2006 National Institutes of Health (NIH) Consensus paper presented recommendations by th...
AbstractThe Ancillary Therapy and Supportive Care Working Group had 3 goals: (1) to establish guidel...
AbstractThe 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for ...
AbstractThe complexity of chronic graft-versus-host disease (GVHD) and the lack of established resea...
AbstractThe 2005 National Institute of Health (NIH) Consensus Conference outlined histopathological ...
AbstractChronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality ...
Chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation i...
AbstractChronic graft-versus-host disease (GVHD) remains a vexing and dangerous complication of allo...
Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality and disa...
In 2005, the National Institutes of Health sponsored a Consensus Development Project on Criteria for...
Based on expert opinion and retrospective data the National Institutes of Health (NIH) Consensus Dev...
AbstractThis consensus document provides an update for pathologists and clinicians about the interpr...
: Positive results from recent clinical trials have significantly expanded current therapeutic optio...
AbstractThe Ancillary Therapy and Supportive Care Working Group had 3 goals: (1) to establish guidel...
: Positive results from recent clinical trials have significantly expanded current therapeutic optio...
AbstractThe 2006 National Institutes of Health (NIH) Consensus paper presented recommendations by th...
AbstractThe Ancillary Therapy and Supportive Care Working Group had 3 goals: (1) to establish guidel...
AbstractThe 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for ...
AbstractThe complexity of chronic graft-versus-host disease (GVHD) and the lack of established resea...
AbstractThe 2005 National Institute of Health (NIH) Consensus Conference outlined histopathological ...
AbstractChronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality ...
Chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation i...
AbstractChronic graft-versus-host disease (GVHD) remains a vexing and dangerous complication of allo...
Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality and disa...
In 2005, the National Institutes of Health sponsored a Consensus Development Project on Criteria for...
Based on expert opinion and retrospective data the National Institutes of Health (NIH) Consensus Dev...
AbstractThis consensus document provides an update for pathologists and clinicians about the interpr...
: Positive results from recent clinical trials have significantly expanded current therapeutic optio...
AbstractThe Ancillary Therapy and Supportive Care Working Group had 3 goals: (1) to establish guidel...
: Positive results from recent clinical trials have significantly expanded current therapeutic optio...